How I treat EBV lymphoproliferation.
暂无分享,去创建一个
[1] H. Einsele,et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.
[2] R. Reshef,et al. Rituximab for PTLD of the CNS: Is It a ‘No-Brainer’? , 2008, Oncology Research and Treatment.
[3] L. Gordon,et al. Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder , 2008, Transplantation.
[4] Allen R. Chen,et al. Successful treatment of a child with late onset T‐cell post‐transplant lymphoproliferative disorder/lymphoma , 2008, Pediatric blood & cancer.
[5] K. Pritchard-Jones,et al. Efficacy and tolerability of high‐dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children , 2007, British journal of haematology.
[6] N. Sebire,et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. , 2007, Blood.
[7] A. Swerdlow,et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. , 2007, Blood.
[8] Chiara Bonini,et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] L. Corey,et al. Adolescents Are More Likely to Develop Posttransplant Lymphoproliferative Disorder After Primary Epstein-Barr Virus Infection Than Younger Renal Transplant Recipients , 2007, Transplantation.
[10] F. Baldanti,et al. Preemptive Therapy of EBV‐Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[11] R. O'reilly,et al. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants , 2007, Immunologic research.
[12] B. Dörken,et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution , 2007, Annals of Hematology.
[13] B. Dörken,et al. Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab , 2007, Transplantation.
[14] A. Rickinson,et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.
[15] C. Klein,et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. , 2007, Blood.
[16] U. Jäger,et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. , 2007, Haematologica.
[17] P. Veys,et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning , 2007, Leukemia & lymphoma.
[18] H. Heslop,et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high‐risk for EBV infection , 2006, Clinical transplantation.
[19] H. Heslop,et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). , 2006, Blood.
[20] J. Wagner,et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. , 2006, Blood.
[21] D. van Baarle,et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] G. Salles,et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. , 2006, Blood.
[23] B. Dörken,et al. Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD) , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] Michael D. Green,et al. Posttransplant lymphoproliferative disease. , 2005, The Pediatric infectious disease journal.
[25] D. Dunn,et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation , 2005, Cancer.
[26] T. Greiner,et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Heslop,et al. Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[28] E. Woodle,et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. , 2005, Transplantation proceedings.
[29] H. Heslop,et al. Cellular Immunity to Epstein‐Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post‐Transplant Lymphoproliferative Disease , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] G. Palù,et al. The real‐time polymerase chain reaction‐guided modulation of immunosuppression enables the pre‐emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation , 2005, British journal of haematology.
[31] R. Krance,et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. , 2004, Transplantation.
[32] R. Krance,et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.
[33] D. Thorley-Lawson,et al. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.
[34] S. Grupp,et al. An unexpectedly high incidence of Epstein–Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma , 2004, Bone Marrow Transplantation.
[35] C. Chang,et al. Humanized anti‐CD20 monoclonal antibody (Rituximab) treatment for post‐transplant lymphoproliferative disorder * , 2003, Clinical transplantation.
[36] F. Miedema,et al. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. , 2003, Blood.
[37] C. Garcia,et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment , 2003, Transplant international : official journal of the European Society for Organ Transplantation.
[38] G. Remuzzi,et al. Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome , 2002, Transplantation.
[39] B. van der Holt,et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.
[40] H. Bazin,et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease1 , 2002, Transplantation.
[41] Paul Martin,et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. , 2002, Blood.
[42] F. Baldanti,et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. , 2002, Blood.
[43] S. Kenney,et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. , 2002, Cancer research.
[44] V. Ribrag,et al. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. , 2001, The New England journal of medicine.
[45] B. van der Holt,et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. , 2001, Blood.
[46] B. Somer,et al. REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1 , 2001, Transplantation.
[47] P. Furth,et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system , 2000, The Lancet.
[48] B. O'neill,et al. Posttransplant primary CNS lymphoma. , 2000, Neuro-oncology.
[49] Zhensheng Liu,et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.
[50] I. Ernberg,et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.
[51] E. Kieff,et al. Epstein-barr virus-induced posttransplant lymphoproliferative disorders , 1999 .
[52] Richard E. Slaughter,et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[53] R. Freeman,et al. Epstein-Barr Virus–Infected Resting Memory B Cells, Not Proliferating Lymphoblasts, Accumulate in the Peripheral Blood of Immunosuppressed Patients , 1999, The Journal of experimental medicine.
[54] G. Ogg,et al. Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.
[55] A. Kliger,et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. , 1997, Transplantation.
[56] K. Lucas,et al. Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts , 1997, Immunological reviews.
[57] Malcolm K. Brenner,et al. Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.
[58] R. Krance,et al. Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease , 1995, British journal of haematology.
[59] H. Heslop,et al. Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.
[60] R. Krance,et al. Epstein-Barr infection after bone marrow transplantation. , 1994, Blood.
[61] M. Nalesnik. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[62] J. Hurwitz,et al. T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients , 2001, Immunologic research.
[63] I. Flinn,et al. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. , 2000, Blood.
[64] E. Kieff,et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. , 1999, Transplantation.
[65] D. Srivastava,et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.
[66] J. Yates,et al. Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.